Overview
- Editors:
-
-
Esther Oliva
-
Franco Muggia
- Provides a unique and thorough guide to uterine cancer from risk and diagnosis to treatment options
- Presents an exhaustive review of current and future therapies, written by the world leaders in the field of gynecological oncology
- Examines the pathology and prognostic factors of uterine and endometrial cancer, with a review of the current state of screening methods
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (15 chapters)
-
-
- Celeste L. Pearce, Karine Chung, Anna H. Wu, Malcolm C. Pike
Pages 1-12
-
- Annekathryn Goodman, Barbara Goff
Pages 13-24
-
- Mansi A. Saksena, Susanna I. Lee
Pages 25-50
-
- Robert A. Soslow, Esther Oliva
Pages 51-86
-
- Jose Palacios, Paola Dal Cin
Pages 87-104
-
- Patricia M. Baker, Esther Oliva
Pages 105-141
-
-
-
- Lea Baer, A. Gabriella Wernicke, Silvia Formenti
Pages 175-192
-
- Nicholas P. Taylor, Matthew A. Powell
Pages 193-216
-
- Franco Muggia, Stephanie V. Blank
Pages 217-222
-
- Halla Nimeiri, Gini F. Fleming
Pages 223-235
-
- Marcela G. del Carmen, Neil S. Horowitz
Pages 237-249
-
- Carolyn Krasner, Martee L. Hensley
Pages 251-265
-
- Franco Muggia, Leslie I. Gold, John Curtin
Pages 267-283
-
Back Matter
Pages 285-296
About this book
For the Editors, the task of writing a Preface is most satisfying. It represents the completion of the book and a moment of reflection on whether the whole is more than the sum of all the parts. And also, one must reflect on how this book is likely to be utilized in this era of rapid communications. The Editors first met in May 2003 at a stimulating Italian symposium on endometrial cancer (organizers Drs. Luigi Frigerio, Roberto Grassi and Andrea Lissoni, with participation of the deans of Italian Gynecologic Oncology, Ugo Bianchi and Constantino Mangioni) that took place at Bergamo and Caravaggio. The impressive gains in biology and clinical trials were further discussed by the two editors and others that are co-authors in this venture on this side of the Atlantic at a 2004 Educational Session at the American Society of Clinical Oncology (ASCO). The pace of progress in various aspects of management of uterine cancer was no- worthy, not only was tumor biology fueling novel hypotheses such as questioning the mesenchymal origin of carcinosarcomas, but knowledge of molecular pathways was beginning to be applied as prognostic and as predictive factors portending benefit from systemic therapies. Surgical staging and sensitive imaging provided the underpinning for refining our treatment algorithms. Finally, a role for che- therapy had finally become established, principally through phase III studies c- paring chemotherapy to radiation in mostly locally advanced stages III and IV that had undergone resection.
Reviews
From the reviews:
“This short monograph comprises 15 chapters written by 31 contributors and covers the epidemiology, pathology, staging, and management of uterine cancers. … This book provides some useful background on endometrial cancer and … helpful for a radiation oncologist with a special interest in gynecologic cancers. … directed primarily at an audience of gynecologic oncologists … .” (David S. Shimm, International Journal of Radiation - Oncology - Biology - Physics, Vol. 77 (2), 2010)
